Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

Chanhee Han; Stefania Bellone; Luca Zammataro; Peter E Schwartz; Alessandro D Santin

doi:10.1016/j.gore.2018.05.011

Binimetinib (MEK162) in recurrent low-grade serous ovarian cancer resistant to chemotherapy and hormonal treatment

Gynecol Oncol Rep. 2018 May 24:25:41-44. doi: 10.1016/j.gore.2018.05.011. eCollection 2018 Aug.

Authors

Chanhee Han¹, Stefania Bellone¹, Luca Zammataro¹, Peter E Schwartz¹, Alessandro D Santin¹

Affiliation

¹ Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.

Abstract

Background: Management of advanced/recurrent low-grade serous ovarian carcinoma (LGOSC) is often challenging. Effective treatment options remain limited for hormone and chemotherapy-resistant LGSOC.CASE: A 65-year-old woman with recurrent widespread LGSOC harboring the KRAS-G12 V hotspot mutation experienced a dramatic clinical response to Binimetinib (MEK162), a mitogen-activated protein kinase (MEK) inhibitor, after failing multiple chemotherapy and hormonal treatments. An 81% reduction of target lesions by RECIST 1.1 over 31 months of response duration was confirmed with serial CT scans. Episodes of drug-related toxicity (pneumonitis) easily resolved without sequelae with the use of oral steroids.

Conclusion: Binimetinib may present a new treatment option for hormone- and chemotherapy-resistant LGSOC harboring KRAS mutations.

Keywords: Binimetinib; Low-grade ovarian cancer; MEK162; Recurrent; Serous; Treatment-resistant.

Publication types

Case Reports